FierceBiotechOriginal article
{"a":[{"_":"Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beat","$":{"href":"/pharma/bristol-myers-delays-cobenfy-alzheimers-psychosis-readout-again-amid-another-quarterly-beat","hreflang":"en"}}]}
Data ReadoutCobenfymilvexianNegative
AI Analysis
Summary
Bristol Myers Squibb has delayed its Cobenfy Alzheimer's psychosis readout and milvexian atrial fibrillation data again. The company reported another quarterly beat, but investors must await the rescheduled trial results.
Importance:6/10
Sentiment:
-0.40
delayAlzheimer'spsychosisatrial fibrillationdata readout
Related Companies
Read the original article
Published by FierceBiotech on July 30, 2026 9:43 AM